Weill Medical College Of Cornell University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1865-01-01

Employees: -

Market Cap: -

Website: http://weill.cornell.edu

Clinical Trials

COVID-19 (Coronavirus Disease-2019) Psychiatric Outcomes

Terminated

Conditions: Covid19
Cognitive Impairment
Mood
Anxiety

First Posted Date: 2021-11-15

Last Posted Date: 2024-04-12

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 2

Registration Number: NCT05119400

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

Pharmacokinetic Evaluation of Serum Testosterone Concentrations After Administration of Clomiphene Citrate

Phase 2

Withdrawn

Conditions: Testosterone Deficiency

Interventions: Drug: Clomiphene Citrate 25mg
Drug: Clomiphene Citrate 50mg

First Posted Date: 2021-10-27

Last Posted Date: 2024-11-04

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 40

Registration Number: NCT05096169

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

A Primary Care-Based Psychosocial Intervention To Improve Cognitive & Depression Outcomes in Older Adults With MCI & Early Stage AD

Not Applicable

Recruiting

Conditions: Depression
Cognitive Impairment
Pain

Interventions: Behavioral: PATH-Pain

First Posted Date: 2021-10-18

Last Posted Date: 2025-05-23

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 100

Registration Number: NCT05081596

Locations: 🇺🇸
Weill Cornell Medicine, White Plains, New York, United States

COVID-19 Respiratory Outcomes Registry

Completed

Conditions: Covid19

Interventions: Other: Questionnaires and Patient Reported Outcomes (PROs)
Diagnostic Test: Nasal Swab COVID-19 reverse transcription polymerase chain reaction test (RT-PCR)
Genetic: Blood Samples for Biomarkers
Diagnostic Test: High Resolution Computed Tomography
Diagnostic Test: Physical Exam and Vital Signs
Diagnostic Test: Medical Research Council Sum Score
Diagnostic Test: Hand Grip Strength
Diagnostic Test: Spirometry
Diagnostic Test: Diffusing Capacity of Carbon Monoxide
Diagnostic Test: 6 Minute Walk Test
Diagnostic Test: Sit to Stand (STS) Measurement

First Posted Date: 2021-10-12

Last Posted Date: 2023-07-27

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 37

Registration Number: NCT05074875

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸
Washington University of St. Louis, Saint Louis, Missouri, United States
🇺🇸
New York University Langone Medical Center, New York, New York, United States

and more 1 locations

Glucose Testing in GDM: Adherence to One- Versus Two-hour Postprandial Glucose Monitoring in Gestational Diabetics

Not Applicable

Completed

Conditions: Gestational Diabetes

Interventions: Other: 2 hour blood glucose monitoring
Other: 1 hour Blood glucose monitoring

First Posted Date: 2021-09-30

Last Posted Date: 2025-05-23

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 140

Registration Number: NCT05062460

Locations: 🇺🇸
New York Prebyterian Hospital Weill Cornell, New York, New York, United States

Utilizing Telemedicine for Hypertension Treatment Lifestyle Modification in Central Harlem

Not Applicable

Withdrawn

Conditions: Hypertension

Interventions: Behavioral: Lifestyle Modification Webinars Focused on Hypertension Control

First Posted Date: 2021-09-30

Last Posted Date: 2023-11-01

Lead Sponsor: Weill Medical College of Cornell University

Registration Number: NCT05062473

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

SPIROMICS Study of Early COPD Progression (SOURCE)

Recruiting

Conditions: COPD, Early-Onset

First Posted Date: 2021-09-05

Last Posted Date: 2025-05-29

Lead Sponsor: University of Massachusetts, Worcester

Target Recruit Count: 1000

Registration Number: NCT05033990

Locations: 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
National Jewish Health, Denver, Colorado, United States

and more 11 locations

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

Phase 2

Recruiting

Conditions: Rectal Cancer

Interventions: Drug: Etrumadenant (AB928)
Radiation: Radiation therapy
Drug: FOLFOX regimen
Drug: Zimberelimab (AB122)

First Posted Date: 2021-08-27

Last Posted Date: 2024-10-01

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 43

Registration Number: NCT05024097

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸
Brooklyn Methodist Hospital - NewYork Presbyterian, New York, New York, United States
🇺🇸
New York Presbyterian Hospital - Queens, New York, New York, United States